EMEA-001501-PIP06-20 - paediatric investigation plan
dupilumab
PIP
Sanofi-Aventis Recherche & Développement
Tel. +33 169745695
E-mail: contact-us@sanofi.com
P/0394/2020 : EMA decision of 23 October 2020 on the granting of a product specific waiver for dupilumab (Dupixent), (EMEA-001501-PIP06-20)